Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Endoscopic Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,973,847

813 payments

Through program year 2025, Endoscopic Research Inc is reported as receiving $1,973,847 in research payments, across 813 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $561,969 170
2024 Research $433,501 159
2023 Research $269,201 98
2022 Research $313,104 132
2021 Research $59,797 24
2020 Research $160,081 105
2019 Research $176,194 125

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,241,851 463 payments
  2. Genentech, Inc. $240,494 169 payments
  3. Roche Products Limited $150,381 103 payments
  4. Sanofi US Services Inc. $133,277 23 payments
  5. Janssen Research & Development, LLC $104,700 35 payments
  6. Adare Pharmaceuticals, Inc. $52,777 5 payments
  7. Celgene Corporation $32,379 2 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $13,000 3 payments
  9. Arena Pharmaceuticals, Inc. $4,936 9 payments
  10. Pfizer Inc. $55 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease $168,112 40 payments
  2. A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis $162,339 88 payments
  3. Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis $150,936 61 payments
  4. A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet $133,277 23 payments
  5. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) $128,859 28 payments
  6. A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohns Disease $117,269 22 payments
  7. ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants $90,341 29 payments
  8. Crohn S Disease Program Ole $84,716 54 payments
  9. An Open Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II III Studies $83,740 62 payments
  10. A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis $82,968 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record